Safety Pharmacology

MEA-Cardiosensor

Do you need a relevant and robust cell model for drug safety testing?
Do you want a more clinically predictive cardiotoxicity assay?

Our Cardiosensor is a reliable and rapid system to test for drug effects on cardiac function, including QT-interval prolongation and arrhythmia in vitro

Cell systems available:
• Stem-cell derived cardiomyocytes
• Primary cardiomyocytes from animal models

The assay is based on the extracellular recording of field action potentials (fAPs) of cardiomyocytes in culture with microelectrode arrays (MEAs). fAPs reflect the concerted activation and inactivation of cardiac ion channels, comparable to an electrocardiogram (ECG) in patients and are thus referred to here as “QT-interval” in vitro.

Drug-induced effects on cardiac function can be observed in our test system, as a prolongation of the fAP duration (“QT-interval in vitro”) and/or arrhythmic beating behaviour of the electrically coupled cardiomyocytes.

Cardiomyocytes after DIV 3 forming a syncytium of electrically coupled cells	Field action potentials (fAPs) recorded from cardiomyocytes at DIV3 representing the "QT interval
Effect of quinidine on "QT-interval" in vitro Effect of quinidine on "QT-interval" in vitro	Dose-response curve for cisapride action on "QT-interval" in vitro Dose-response curve for cisapride action on "QT-interval" in vitro
Drug-induced arrhythmia in cardiomyocytes (DIV 3 on MEA) Drug-induced arrhythmia in cardiomyocytes (DIV 3 on MEA)